Novocure Ltd., a commercial stage, private oncology company, announced today that Wilco Groenhuysen has been appointed as chief financial officer, a newly created position.  Mr. Groenhuysen will assume leadership for global finance functions and join the executive management team that is leading the worldwide launch of Novocure's Tumor Treating Fields (TTF) cancer therapy devices. <br /> <br />Prior to joining Novovcure, Mr. Groenhuysen was executive vice president and chief financial officer of Cephalon Inc., through its acquisition by Teva Pharmaceutical Industries Ltd. in 2011. At Cephalon, Mr. Groenhuysen was responsible for worldwide finance, commercial operations, investor relations and risk management.  Mr. Groenhuysen led financings in total of over $1.0 billion from equity, convertible debt and credit facilities for Cephalon.<br /> <br />Prior to joining Cephalon in 2007, Mr. Groenhuysen spent 20 years with Philips Electronics in various assignments in Europe, Asia and the United States.  At the time he left Philips, Mr. Groenhuysen was the CFO and senior vice president of Philips Electronics North America Corporation.<br /> <br />"Wilco Groenhuysen has a history of success leading financial operations of complex, rapidly growing, global businesses. His rare combination of experience in the electronics industry with Philips and in the oncology industry with Cephalon makes him exceptionally well-qualified to serve as our CFO," said William F. Doyle, Novocure's executive chairman.  "Wilco will play an essential role in executing Novocure's mission to bring TTF therapy to cancer patients."<br /> <br />"I am thrilled to join such a talented management team and rapidly expanding company," said Mr. Groenhuysen. "We have the opportunity to transform cancer care for patients around the world."<br />"Novocure has been fortunate to attract dedicated, experienced world class executives such as Wilco Groenhuysen to its management team," said Asaf Danziger, Novocure CEO.  "I look forward to working with Wilco over the coming years to continue Novocure's growth as a global oncology company."<br />